# Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera

> **NCT01949805** · PHASE3 · COMPLETED · sponsor: **AOP Orphan Pharmaceuticals AG** · enrollment: 257 (actual)

## Conditions studied

- Polycythemia Vera

## Interventions

- **DRUG:** Peg-P-IFN-alpha-2b (AOP2014)
- **DRUG:** Hydroxyurea

## Key facts

- **NCT ID:** NCT01949805
- **Lead sponsor:** AOP Orphan Pharmaceuticals AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 257 (ACTUAL)
- **Last updated:** 2016-11-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01949805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01949805, "Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01949805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*